Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors

Pharmacotherapy of acute myeloid leukemia (AML) remains challenging, and the disease has one of the lowest curability rates among hematological malignancies. The therapy outcomes are often compromised by the existence of a resistant AML phenotype associated with overexpression of ABCB1 and ABCG2 tra...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorf, Ales, Sucha, Simona, Morell, Anselm, Novotna, Eva, Staud, Frantisek, Zavrelova, Alzbeta, Visek, Benjamin, Wsol, Vladimir, Ceckova, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352292/
https://www.ncbi.nlm.nih.gov/pubmed/32560251
http://dx.doi.org/10.3390/cancers12061596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352292/
https://www.ncbi.nlm.nih.gov/pubmed/32560251
http://dx.doi.org/10.3390/cancers12061596

Ejemplares similares